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Abstract
Background: The SCFskp2 complex is an E3 ubiquitin ligase that is known to target a number of
cell cycle regulators, including cyclin-dependent kinase inhibitors, for proteolysis. While its role in
regulation of cell division has been well documented, additional functions in differentiation,
including in the nervous system, have not been investigated.
Results: Using Xenopus as a model system, here we demonstrate that skp2 has an additional role
in regulation of differentiation of primary neurons, the first neurons to differentiate in the neural
plate. Xenopus skp2 shows a dynamic expression pattern in early embryonic neural tissue and
depletion of skp2 results in generation of extra primary neurons. In contrast, over-expression of
skp2 inhibits neurogenesis in a manner dependent on its ability to act as part of the SCFskp2
complex. Moreover, inhibition of neurogenesis by skp2 occurs upstream of the proneural gene
encoding NeuroD and prior to cell cycle exit. We have previously demonstrated that the Xenopus
cyclin dependent kinase inhibitor Xic1 is essential for primary neurogenesis at an early stage, and
before these cells exit the cell cycle. We show that SCFskp2 degrades Xic1 in embryos and this
contributes to the ability of skp2 to regulate neurogenesis.
Conclusion: We conclude that the SCFskp2 complex has functions in the control of neuronal
differentiation additional to its role in cell cycle regulation. Thus, it is well placed to be a co-
ordinating factor regulating both cell proliferation and cell differentiation directly.
Background
Ubiquitin-mediated proteolysis has recently emerged as a
central player in regulating destruction of proteins con-
trolling cell fate determination, cell proliferation and cell
differentiation [1,2]. Indeed, coordinating stability of pro-
teins involved in these three processes is an efficient way
for cells to decide to divide or to undergo differentiation.
Polyubiquitination, which targets proteins for destruc-
tion, is brought about by a multi-enzyme cascade, typi-
cally involving E1 ubiquitin-activating enzymes, E2
Published: 14 December 2007
Neural Development 2007, 2:27 doi:10.1186/1749-8104-2-27
Received: 3 May 2007
Accepted: 14 December 2007
This article is available from: http://www.neuraldevelopment.com/content/2/1/27
© 2007 Boix-Perales et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Neural Development 2007, 2:27 http://www.neuraldevelopment.com/content/2/1/27
Page 2 of 16
(page number not for citation purposes)
ubiquitin-conjugating enzymes and E3 ubiquitin ligases
[3]. Specificity for particular substrates resides in the E3
subunit, which is itself often a multi-subunit complex.
The largest group of E3 ligases is the ring-finger domain
family and within this family several so called SCF E3
ligases are known to target proteins important for mainte-
nance of the balance between proliferation and differenti-
ation [4-6]. One of the best studied ligases in this family
is SCFskp2, which is composed of a cullin-1 scaffold,
bound directly to the Ring finger protein Rbx1 and to
Skp1 [4-9]. Specificity for ubiquitination resides in the
skp2 subunit, which associates with Skp1 via its F box.
SCFskp2 has been shown to target a growing number of
proteins important in cell cycle progression for ubiquitin-
mediated proteolysis. These include the transcription fac-
tors E2F1 [10] and c-myc [11,12], and the cdk inhibitors
(cdkis) p21 Cip1 [13,14] and p27Kip1 [15], although the
physiological relevance of some of these potential sub-
strates has been questioned.
Importantly, targets of SCFskp2, of which p27Kip1 is the
most studied, must generally be phosphorylated in a cell
cycle dependent manner to be targeted by skp2 for polyu-
biquitination and destruction [16-18]. Xenopus skp2 has
recently been cloned and has been shown to target the
Xenopus cdki Xic1 [19,20] for degradation in vitro and in
egg extracts [21]. However, in this case Xic1 appears not to
require phosphorylation for targeting.
We have previously showed that Xic1 has an essential role
in differentiation of primary neurons, the first neurons to 
differentiate in the neural plate in Xenopus [22]. Neural
differentiation in this system is driven by the neurogenic
transcription factor, Neurogenin (XNgnr1), which is
expressed in scattered neural precursors in the neural plate
arranged in three stripes lateral to the midline [23].
XNgnr1 transcriptionally upregulates another basic helix-
loop-helix (bHLH) transcription factor NeuroD, whose
expression coincides with cell cycle exit and terminal neu-
ral differentiation [24]. Interestingly, we have shown that
Xic1 is not required at these late stages downstream of
NeuroD for cell cycle exit or differentiation. Instead, Xic1
acts at an early stage of neurogenesis, in parallel with
XNgnr1, where it appears to stabilise the XNgnr1 protein
[22]. Moreover, this function is separable from the ability
of Xic1 to inhibit overall cdk kinase activity [22]. Thus,
Xic1 has distinct roles in cell cycle regulation and differen-
tiation, making it an appealing candidate for a protein
that coordinates these two functions.
Skp2, by regulating the stability of cdkis as well as addi-
tional targets such as c-myc and E2F1, is also well placed
to play a role in coordinating proliferation and differenti-
ation. A skp2 null mouse has been generated, which
although smaller than wild type, is phenotypically grossly
normal despite an increase in polyploidy, multiple cen-
trosomes and apoptosis [15]. A skp2-/- p27Kip1-/- mouse
has also been generated [25], which appears similar but
not identical to the p27Kip1-/- mice, indicating that,
while p27Kip1 may be its main target, SCFskp2 may ubiq-
uitinate other important substrates. In mice, however, the
presence of three cdkis and other redundancies makes
analysis of the role of skp2 in proliferation and differenti-
ation during development problematic.
Importantly, targets of SCFskp2, of which p27Kip1 is the
most studied, must generally be phosphorylated in a cell
cycle dependent manner to be targeted by skp2 for polyu-
biquitination and destruction [16-18]. Xenopus skp2 has
recently been cloned and has been shown to target the
Xenopus cdki Xic1 [19,20] for ubiquitination in vitro and
for degradation in egg extracts [21]. However, in this case
Xic1 appears not to require phosphorylation for targeting.
We find that Xenopus skp2 (skp2) shows dynamic expres-
sion in the neural plate and neural tube, indicating that it
is well placed to regulate neural differentiation in a stage-
specific manner. Loss of skp2 protein after morpholino
injection has no effect on the cell cycle but results in dif-
ferentiation of extra primary neurons, while over-expres-
sion of skp2 inhibits neurogenesis and this depends on
the presence of an F box. Skp2 can degrade Xic1 in vivo and
this can account for some, but not all, of skp2's ability to
regulate primary neurogenesis. Therefore, skp2 is well
placed to directly regulate the balance between prolifera-
tion and differentiation, in addition to a potential role in
cell cycle control.
Results
Skp2 is expressed at significant but low levels before the
mid-blastula transition in Xenopus  [21]. However, after
the mid-blastula transition, levels rise and remain con-
stant through neural plate stages, when primary neuro-
genesis is occurring. To determine the spatial expression
pattern of skp2 during development, in situ hybridisation
was performed on embryos of different stages (Figure 1).
skp2 RNA is expressed broadly early in development (data
not shown) but post-gastrulation by stage 13, it is found
concentrated in anterior placodes and extending posteri-
orly, lateral to the edges of the neural plate (Figure 1a). By
stage 14, while remaining in the placode and anterior neu-
ral folds, skp2 message is excluded from the neural plate
proximal to the midline and myotome (Figure 1b),
although it is detectable in lateral neural plate regions. For
comparison, Xic1 expression was investigated in stage 14
embryos (Figure 1c). Xic1 is strongly expressed in lateral,
intermediate and medial stripes corresponding to the
positions where primary neurons will differentiate, as wellNeural Development 2007, 2:27 http://www.neuraldevelopment.com/content/2/1/27
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as showing strong staining in the underlying myotome
[26]. Thus, at this stage, skp2 expression in the lateral
folds overlaps with that of Xic1 in the forming lateral
stripe of primary neurons.
We also investigated the expression of skp2 relative to
Xic1 in the late neural plate in embryos that had under-
gone in situ hybridisation to detect expression of the indi-
vidual genes, which were subsequently sectioned (Figure
1h,i). As expected, Xic1 is expressed in deep layer cells, in
addition to staining in the underlying myotome and
notochord (which can be distinguished by light blue
staining due to poor penetration by the BM purple sub-
strate; see Materials and methods). Skp2 staining, by con-
trast, is weaker but is present in both the superficial and
deep layers of the neural plate in a region overlapping
Xic1 expression.
By stage 17, when the neural tube begins to close, skp2
message is found posteriorly in the neural folds, as well as
remaining in the placodes, eye field and brain regions
(Figure 1d). Primary neurons only form from the deep
layer of the neural plate while superficial layer cells
remain undifferentiated at this stage [27]. By tailbud stage
25, skp2 message is expressed in the neural tube, eye and
branchial arches (Figure 1e). At a similar stage (stage 26;
Figure 1f), Xic1 is also expressed in the neural tube, eye
and branchial arches but additional staining is seen in the
myotome where skp2 is undetectable. By stage 33, skp2
expression remains strongest in the head (Figure 1g).
Expression of skp2 and Xic1 Figure 1
Expression of skp2 and Xic1. Whole-mount in situ hybridisation at indicated stages show expression of (a,b,d,e,g) skp2 and 
(c,f) Xic1. (a,c) Dorsal view with anterior toward the bottom. (b,d) Anterior view with dorsal toward the top. (e-g) Lateral 
view with anterior to the left. (h,i) Expression of skp2 and Xic1, respectively, in a vibratome section of stage 16 embryos; pri-
mary neurons are indicated with black arrows. Ep, epidermis; I, intermediate stripe; L, lateral stripe; M, medial stripe; My, myo-
tome; Nf, neural folds; Not, notochord; Np, neural plate; Nt, neural tube; P, placodes.Neural Development 2007, 2:27 http://www.neuraldevelopment.com/content/2/1/27
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Thus, skp2 is expressed at the right time and in the right
place to be playing a role in primary neurogenesis. Inter-
estingly, at early neural plate stages skp2 RNA is excluded
from the medial areas expressing the potential target Xic1
(compare Figure 1b and 1c), although overlap is seen in
the lateral neural folds (Figure 1h,i). However, as neurula-
tion proceeds, skp2 expression expands to the mid-line
(Figure 1d). Therefore, skp2 expression is dynamic and is
consistent with a stage dependent role in regulation of
Xic1 protein, an in vitro target in primary neurons [21]. As
Xic1 is essential for primary neurogenesis, skp2 is also
well placed for regulating this process. We have investi-
gated this further.
To determine whether skp2 may play a role in regulation
of primary neurogenesis, we designed a skp2 morpholino
(skp2 Mo) to inhibit skp2 protein expression, along with
a matched control morpholino (Con Mo) that has five
base changes, so would be unable to bind to skp2 mes-
sage. As expected, skp2 Mo but not Con Mo was able to
prevent translation of co-injected skp2 message (Figure
2a), although skp2Mo is unable to target a modified skp2
that is missing the first six base-pairs after the initiator
ATG (skp2 1–2). We then injected increasing amounts of
skp2 Mo into two of two cells and performed western blot
analysis to look at the level of endogenous skp2 protein
(Figure 2b). While endogenous skp2 is expressed at low
levels, probably as it is an unstable protein [28], it is nev-
ertheless clearly detected in both uninjected embryos and
those injected with 40 ng Con Mo (Figure 2b, lanes 4 and
5). In contrast, 20 ng of skp2 Mo substantially inhibited
expression of skp2 compared to uninjected or Con Mo
injected embryos (Figure 2b, lane 1), and at 30 ng and 40
ng of skp2 Mo, skp2 protein was undetectable (Figure 2b,
lanes 2 and 3). Thus, skp2 Mo specifically blocks transla-
tion of skp2 message, resulting in an absence of detectable
skp2 protein, while a matched control morpholino has no
effect.
We then investigated the effect of loss of skp2 on differen-
tiation of primary neurons, by injecting skp2 Mo or Con
Mo into one cell of a two-cell embryo along with β-galac-
tosidase (ßgal) RNA as a lineage tracer. As the first plane
of cleavage should bisect the embryo along the left/right
axis, the injected and uninjected sides of the embryo can
be compared. Embryos were allowed to develop to stage
15, fixed and then in situ hybridisation was performed to
determine neural β-tubulin (nßt) expression, which is
expressed in differentiated primary neurons (Figure 2c–g).
Embryos were scored according to the number of neurons
on the injected versus the uninjected side. Examples of
representative embryos displaying the phenotypes
described (Figure 2c) are given (Additional file 1). Skp2
Mo injection resulted in a subtle but reproducible increase
in the number of primary neurons on the injected side
versus the uninjected side of the embryo, generally proxi-
mal to or within the usual stripe of primary neurogenesis
(Figure 2c, d, f; 20 ng, n = 120 embryos; 30 ng, n = 123
embryos; 40 ng, n = 100 embryos). This effect was
dependent on the dose of skp2 Mo injected; the higher the
dose of skp2 Mo, the greater the percentage of embryos
showing an increase in neuron number (Figure 2c). A very
small proportion of embryos injected with skp2 Mo at the
highest doses showed a reduction of neurons. However,
this was not strictly dose dependent and a similar, albeit
slightly smaller, effect was also seen with the highest dose
of Con Mo (30 ng, n = 73; 40 ng, n = 108), so it is unlikely
to be a specific effect of loss of skp2 protein.
The increase in the number of primary neurons on the
injected side was subtle and somewhat variable in whole-
mount embryos. To look more closely, stage 15 embryos
were sectioned and analyzed by in situ hybridisation for
nßt expression. Extra primary neurons were clearly seen
after skp2Mo injection on the injected side only, and
these were confined, as usual, to the deep layer of cells of
the neuroectoderm (Figure 2f, arrow). Interestingly, we
usually saw an increase in primary neurons lateral to or
within the lateral stripe rather than at the mid-line. Cells
in the lateral stripe will go on to form the sensory neurons
and this is the region of neural plate-stage embryos where
in situ hybridisation staining for both Xic1 and skp2 over-
lap (Figure 1b, c, h, i).
Thus, loss of skp2 protein leads to a moderate but dose-
dependent and significant increase in the number of pri-
mary neurons. Notably extra neurons form generally
dorso-laterally and near to or within the established
stripes in the deep layer of the neural plate but not ectop-
ically significantly ventrally (Figure 2d, f). A similar effect
is seen on over-expression of the skp2 target, Xic1 [22].
SCFskp2 degrades cdkis [10,13,14,29-32]. Therefore, loss of
skp2 might be expected to result in a slowing of the cell
cycle, and indeed skp2 knockout mice are small and their
cells display a reduced growth rate [15]. As proliferation is
thought to be incompatible with differentiation in neu-
rons, it is therefore possible that skp2 Mo is promoting
neurogenesis by inducing cell cycle exit in the neural
plate. To investigate this possibility, we injected skp2 Mo
or Con Mo into one cell of a two cell embryo and allowed
these embryos to develop to neural plate stage before
staining for the mitotic marker phosphohistone H3
(pH3) [33] (Figure 2h, i). Numbers of pH3-expressing
cells were counted in a fixed area of the neural plate on
injected and uninjected sides and compared (Figure 2h',
i'). There was no significant difference in the number of
mitotic cells after injection of either skp2 Mo or Con Mo
(n = 31 embryos and n = 38 embryos, respectively). There-
fore, loss of skp2 does not promote neural differentiation Neural Development 2007, 2:27 http://www.neuraldevelopment.com/content/2/1/27
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Loss of skp2 protein promotes primary neurogenesis Figure 2
Loss of skp2 protein promotes primary neurogenesis. (a) Embryos were injected with wild-type (Wt) skp2, skp2 1–2 alone or in combi-
nation with skp2 Mo or Con Mo as indicated. Protein (30 μg) from a stage 15 embryo was western blotted to determine skp2 levels; 
tubulin was used as a loading control. (b) Western blot for endogenous skp2 protein levels on stage 15 embryos that were injected with 
20 ng, 30 ng, or 40 ng skp2 Mo or 40 ng Con Mo at the one cell stage, arrow to skp2 protein band. In vitro translated (IVT) skp2 protein 
is run in lane 6, and alpha-tubulin was used as a loading control. (c) The percentages of embryos with mild increase, no change, or mod-
erate or substantial reduction of nßt positive cells on the injected side relative to the uninjected side for 20 ng, 30 ng, and 40 ng skp2 Mo, 
or 30 ng and 40 ng Con Mo (see Additional file 1 for photographs of representative embryos). (d,e) Embryos were injected with 30 ng 
skp2 Mo (d) or 30 ng Con Mo (e) in one blastomere at the two cell stage, along with ßgal mRNA as a lineage tracer, and analyzed for nßt 
mRNA expression at stage 15 ((d) arrow to show expansion of primary neurons). The view is dorsal with injected side to the right. (f,g) 
In situ hybridisation sections, which are transverse across the centre of the embryo, with injected side to the right (f) Section of an early 
neurula embryo injected with 30 ng skp2 Mo, indicating nßt upregulation by skp2 protein depletion. (g) Section of a mid neurula embryo 
injected with 30 ng Con Mo showing no difference in nßt distribution. Arrows (f, g) denoting staining of nßt in primary neurons. (h,i) 
Whole mount stage 15 embryos immunostained (red) to detect pH3 after injection of 30 ng skp2 Mo (h) or 30 ng Con Mo (i) in one blas-
tomere at the two cell stage. ßgal mRNA was co-injected and X-Gal staining (blue) was performed to reveal injected side. Dorsal views 
with injected side to the right. (h',i') Detail of pH3 cells on the injected side relative to the uninjected side of representative embryos 
(boxed area in (h,i), dashed line is dorsal mid-line separating injected and uninjected halves).Neural Development 2007, 2:27 http://www.neuraldevelopment.com/content/2/1/27
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by forcing cell cycle exit. A thickening of the epidermis
was sometimes seen in sections (Figure 2f), indicating
some alteration in neuroectodermal architecture. How-
ever, our pH3 analysis indicates this is not a result of
increased proliferation of neuroectodermal cells.
While skp2 targets need to be phosphorylated prior to
ubiquitination, the absolute amount of skp2 may also be
important in determining target degradation; levels of
skp2 protein itself are regulated in a cell cycle dependent
manner [25,34] while its levels are elevated in a number
of human tumours [3,35-54]. Therefore, we next deter-
mined the effect of over-expression of skp2 RNA on differ-
entiation of primary neurons (Figure 3a–c,f). As controls,
we used the mutant of skp2 that has had the F box Skp1
binding domain deleted (F box skp2), so is impaired in its
ability to target substrates for destruction [21]. This F Box-
deleted form of skp2 has been shown to be unable to tar-
get Xic1 for destruction in vitro [21]. As an additional con-
trol, we injected RNA encoding Xenopus MAFbx. MAFbx is
a related ring finger E3 ligase that can ubquitinate MyoD
in mammals [55] and, therefore, would not be expected to
affect primary neurogenesis.
To investigate the effect of over-expression of skp2, RNAs
were injected into one cell of two cell embryos along with
ßgal RNA, and then embryos were allowed to develop
until stage 15. In situ hybridisation was subsequently per-
formed to detect nßt expression; 84% of embryos (n =
359) injected with wild-type skp2 showed reduced nßt
expression on the injected side (Figure 3a). In contrast,
neither F box skp2 (Figure 3b) nor MAFbx (Figure 3c)
affected nßt staining (100% n = 65 and 92% n = 49 unaf-
fected, respectively). Thus, over-expression of skp2 inhib-
its neuronal differentiation and this is dependent on the
ability of skp2 to interact with the SCF complex and,
hence, target substrates for ubiquitin-mediated proteoly-
sis. The effect of skp2 over-expression is dose-dependent;
Over-expression of skp2 blocks primary neurogenesis and reduces cell proliferation Figure 3
Over-expression of skp2 blocks primary neurogenesis and reduces cell proliferation. (a-e) Embryos were injected with 1 ng wild-type 
(Wt) skp2 (a,d), 1 ng FBox skp2 (b,e), or 1 ng Wt MAFbx (c) mRNA, along with ßgal mRNA as a lineage tracer, in one blastomere at the 
two cell stage. Embryos were analyzed for expression of nßt mRNA (a-c) at stage 15. Dorsal views with injected side to the right. (d,e) 
Whole mount stage 15 embryos immunostained (red) to detect pH3 after injection of 1 ng Wt skp2 (d), or 1 ng FBox skp2 (e) mRNA, 
along with ßgal mRNA as a lineage tracer, in one blastomere at the two cell stage. Dorsal views with injected side to the right. (d',e') 
Detail of pH3-positive cells on the injected side relative to the uninjected side (boxed area in (d,e), dashed line is dorsal mid-line separat-
ing injected and uninjected halves). (f) Embryos were injected with 250 pg, 500 pg or 1 ng Wt skp2 mRNA (n = 41, 83, 87 embryos, 
respectively) in one blastomere at the two cell stage. Embryos were analyzed for expression of nßt mRNA at stage 15. Data shown in (f) 
are the percentages of embryos with no change, or moderate or substantial reduction of nßt positive cells on the injected side relative to 
the uninjected side for each injection (see Additional file 1 for photographs of representative embryos).Neural Development 2007, 2:27 http://www.neuraldevelopment.com/content/2/1/27
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embryos injected with 250 pg skp2 mRNA showed only a
modest decrease in neurons but this effect was progres-
sively more pronounced on increasing skp2 mRNA, up to
1 ng, where more than 80% of embryos were affected (Fig-
ure 3f).
Elevated levels of skp2 correlate with cancer where cells
proliferate inappropriately [38,56]. Moreover, skp2 over-
expression alone induces quiescent fibroblasts to replicate
their DNA in low serum [30]. Such an increase in cell pro-
liferation might be expected to inhibit neural differentia-
tion and, indeed, over-expression of cyclin A2/cdk2 alone
in Xenopus embryos inhibits primary neurogenesis [57].
Thus, we investigated whether skp2 over-expression alone
could promote proliferation in early Xenopus embryos by
injection of skp2 mRNA into one cell of a two cell embryo
followed by analysis of pH3 staining in the neural plate.
Unexpectedly, skp2 over-expression led to a 24% decrease
in pH3-expressing cells on the injected side (p < 0.001, n
= 27 embryos; Figure 3d). Moreover, the F box mutant of
skp2 also produced an 18% decrease in pH3 cells (p <
0.001, n = 17 embryos; Figure 3e). This indicates that
effects on proliferation are modest and are not due to the
specific targeting of skp2-dependent substrates for ubiqui-
tin-mediated proteolysis, and additionally cannot explain
the ability of wild-type skp2 to inhibit neurogenesis.
Depletion of skp2 promotes primary neurogenesis (Figure
2) while over-expression of skp2 inhibits neuron forma-
tion (Figure 3). To demonstrate the specificity of these
effects, we co-injected skp2 Mo or Con Mo along with
RNA encoding skp2 missing the first six base-pairs after
the ATG start site, which is not targeted by the skp2 Mo.
Western blotting of protein lysates from stage 15 embryos
revealed that skp2 Mo knocks down exogenous skp2 pro-
tein effectively, but is unable to reduce levels of this non-
targeted skp2 protein (Figure 2a).
Injection of skp2 Mo resulted in a modest increase in nßt-
expressing cells (Figure 4a, f; 33%, n = 51 embryos), while
injection of non-targeted skp2 alone resulted in 80% of
embryos showing a decrease in neurogenesis (Figure 4b, f,
n = 79 embryos). Co-injection of skp2 Mo and skp2
mRNA resulted in an intermediate phenotype (Figure 4c,
f). Thus, the absolute level of skp2 protein is crucial for
regulating the number of primary neurons forming in the
neural plate.
Cell cycle exit of primary neurons is thought to occur
downstream of NeuroD [58]. To determine where skp2
acts in the pathway of neurogenesis, we co-injected wild-
type or F Box skp2 mRNA along with XNgnr1 mRNA, the
earliest acting proneural gene [23], or mRNA for its down-
stream target NeuroD [24] (Figure 5). Embryos were fixed
at stage 15 and stained for nßt expression. Over-expres-
sion of XNgnr1 induces extensive ectopic neurons on the
injected side (Figure 5a; 100%, n = 152 embryos). How-
ever, when skp2 is co-injected, 86% of embryos showed
reduced neuronal staining compared to XNgnr1 alone
(Figure 5b; n = 113 embryos). In contrast, F Box skp2 had
no effect on XNgnr1's ability to induce neurons (Figure
5c; 100%, n = 27 embryos). Over-expression of the down-
stream bHLH neurogenic transcription factor NeuroD
also induces substantial ectopic neurogenesis (Figure 5d;
100%, n = 70 embryos), but this was not inhibited by co-
injection of either wild-type or F Box skp2 (Figure 5e, f;
both 100%, n = 80 and n = 35 embryos, respectively).
Therefore, over-expression of skp2 inhibits neurogenesis
upstream of NeuroD, but in parallel with, or downstream
of, XNgnr1. As primary neurons are thought to exit the cell
cycle downstream of NeuroD expression [58], taken
together with results from pH3 staining (Figures 2h and
3d), skp2 appears not to regulate primary neurogenesis by
regulating cell cycle progression and exit.
Skp2 has been demonstrated in the mammalian systems
to degrade several substrates known for their roles in reg-
ulating proliferation and/or differentiation, including
p27Kip1, p21Cip1, c-myc, E2F-1 and p107 [10,13,14,29-
31,59]. Xic1, the Xenopus  homologue of p27Kip1 and
p21Cip1, is also targeted by skp2 for ubiquitin-mediated
proteolysis [21]. We have previously shown that Xic1
plays an essential role in primary neurogenesis in parallel
with XNgnr1 and prior to cell cycle exit [22]. As over-
expression of skp2 inhibits neurogenesis at this stage,
skp2 may regulate primary neurogenesis by controlling
the levels of Xic1 protein. We have investigated this possi-
bility further.
Skp2 can target Xic1 for ubiquitination in a fully reconsti-
tuted biochemical assay and can target it for destruction in
vitro using extracts of Xenopus eggs [21]. We wished to
determine whether over-expressed skp2 could promote
Xic1 degradation. Firstly, we compared the level of expres-
sion of wild-type skp2 and the F-box-deleted mutant skp2
(Figure 6a). After injection into fertilised eggs, embryos
were harvested at stage 9 and western blotting performed
to detect over-expressed skp2 protein. Both wild-type and
F box skp2 were detected. To determine whether over-
expressed skp2 can target Xic1 for degradation in develop-
ing embryos, we injected increasing amounts of skp2 RNA
up to 1 ng with or without RNA encoding Xic1, and then
performed western blot analysis to look at Xic1 levels at
stage 13 (Figure 6b). When injected alone, Xic1 protein
accumulated to considerable levels (Figure 6b, lane 1).
Levels of Xic1 protein dropped on co-injection with skp2,
showing a maximal decrease at 500 pg co-injected skp2
message (Figure 6b, lanes 2–4). Therefore, while increas-
ing skp2 levels did promote Xic1 destruction, this was not
a linear relationship at high levels of skp2, perhaps result-Neural Development 2007, 2:27 http://www.neuraldevelopment.com/content/2/1/27
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ing from saturation of the rest of the SCFskp2 machinery
required for skp2 to act catalytically. Skp2-mediated deg-
radation of Xic1 is dependent on an intact F Box (Figure
6c).
Skp2 message is most strongly expressed in the neural
plate, underlying myotome and the notochord at stage 15.
Xic1 is also transiently expressed in scattered cells in the
epidermis at around stages 12–13 [22] so protein may still
be present in the skin of the embryo as well as these other
tissues. To determine whether skp2 can target endogenous
Xic1 for degradation in the neural plate, embryos were
injected with wild-type or F Box skp2 dorsally along with
green fluorescent protein as a lineage tracer. The dorsal
region encompassing the neural plate and anterior neural
folds of stage 16 embryos expressing green fluorescent
protein in this area were dissected out, and the levels of
Xic1 protein compared by western blotting. Over-expres-
sion of wild-type skp2 significantly decreased the level of
endogenous Xic1 protein compared to neural plates from
uninjected embryos (Figure 6d). In comparison to
wildtype skp2, Fbox skp2 had no effect on the level of
endogenous Xic1 protein (Figure 6d), consistent with its
impaired ability to target Xic1 to the SCF complex.
Over-expression of skp2 counteracts the effect of skp2 Mo on neural differentiation Figure 4
Over-expression of skp2 counteracts the effect of skp2 Mo on neural differentiation. (a-e) Embryos were injected with 30 ng skp2 Mo 
(a), 30 ng Con Mo (d), or 1 ng skp2 (missing first two amino acids) mRNA (b) alone, or together as labelled (c,e), in one blastomere at the 
two cell stage. ßgal mRNA was co-injected as a lineage tracer. Embryos were analyzed for expression of nßt mRNA at stage 15. Dorsal 
views with injected side to the right. (f) Percentages of embryos with moderate increase, no change, or moderate or substantial reduc-
tion of nßt positive cells on the injected side relative to the uninjected side for each injection.Neural Development 2007, 2:27 http://www.neuraldevelopment.com/content/2/1/27
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Interestingly, over-expression of skp2 did not result in
complete degradation of either endogenous Xic1 (Figure
6d) or Xic1 translated from co-injected cDNA (Figure 6b,
c). As well as expression in the epidermis, primary neu-
rons and neuronal placodes, Xic1 becomes increasingly
strongly expressed in the myotome as neural plate stages
progress (Figure 1). Xic1 is absolutely required for myo-
tomal muscle differentiation in Xenopus [26], so if it can
be degraded by skp2 in this tissue we would expect skp2
over-expression to inhibit myogenesis. Hence, we looked
to see whether wild-type skp2, but not Fbox skp2, could
inhibit muscle differentiation. Interestingly, and unlike
differentiation of primary neurons, over-expression of
skp2 did not inhibit early or late muscle differentiation
(Figure 6e–h), indicating that Xic1 protein cannot be tar-
geted for destruction in this tissue. This would account for
our observation that only a proportion of Xic1 can be
degraded by skp2 over-expression; Xic1 protein in the
myotome would remain stable.
Xic1 over-expression promotes primary neurogenesis
[22]. To investigate further whether Xic1 is a target for
skp2 in the neural plate during neurogenesis in vivo, we
injected skp2, Xic1 or both mRNAs into one cell of two
cell embryos, allowed embryos to develop to stage 15 and
then looked for nßt expression (Figure 7). On injection of
skp2, 50% of embryos showed a substantial reduction in
nßt, often resulting in an absence of neurons on the
injected side, while a further 39% showed a moderate
reduction (n = 155). In contrast, 100% of embryos
injected with Xic1 showed a moderate increase in the
numbers of neurons (n = 131). When both mRNAs were
co-injected, we saw a selection of intermediate pheno-
types; 24% showed a substantial reduction in neurons,
38% a moderate reduction, 10% no difference, and 28%
a moderate increase (Figure 7d).
Thus, over-expression of Xic1 can partially rescue the
effect of skp2 over-expression. However, it is of note that,
after mRNA injection, Xic1 protein accumulates to levels
considerably above endogenous (for example, compare
lanes 1, 4 and 5 in Figure 6b), yet this is not enough to
fully reverse the effects of skp2 over-expression on inhibi-
tion of neurogenesis. Thus, we consider it likely that skp2
skp2 inhibits primary neurogenesis between XNgnr1 and NeuroD Figure 5
skp2 inhibits primary neurogenesis between XNgnr1 and NeuroD. (a-f) Embryos were injected with XNgnr1 (a) or NeuroD 
(d) mRNA alone, or together with Wt skp2 (b,e) or FBox skp2 (c,f) mRNA, in one blastomere at the two cell stage. ßgal 
mRNA was co-injected as a lineage tracer. Embryos were analyzed for expression of nßt mRNA at stage 15. Dorsal views with 
injected side to the right.Neural Development 2007, 2:27 http://www.neuraldevelopment.com/content/2/1/27
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is regulating levels of both Xic1 and other factors required
for primary neurogenesis. These potentially novel sub-
strates remain to be identified.
Discussion
Ubiquitin-mediated proteolysis has recently emerged as a
central regulator of numerous cellular pathways, although
the role of E3 ubiquitin ligases in developmental proc-
esses has been poorly studied. We have investigated the
Over-expression of skp2 can degrade p27Xic1 Figure 6
Over-expression of skp2 can degrade p27Xic1. (a) Western blot for embryos at stage 9, either uninjected or injected with 1 ng mRNA 
encoding wild-type (WT) skp2 or F box skp2, as labelled; tubulin demonstrates equal loading. (b) Western blot for Xic1 levels in 
embryos injected with 50 pg Xic1 mRNA and increasing doses (100 pg to 1 ng) of skp2 mRNA at the one cell stage. Embryos were har-
vested at stage 13; tubulin demonstrates equal loading. (c) Western blot for Xic1 levels in embryos harvested at stage 7 that were 
injected with 1 ng WT skp2 or 1 ng FBox skp2 mRNA at the one cell stage along with 50 pg Xic1 mRNA; tubulin demonstrates equal 
loading. (d) Western blot for Xic1 levels in neural plates harvested at stage 16 from embryos that were injected with 1 ng WT skp2 or 1 
ng FBox skp2 mRNA into the animal pole of a fertilised egg. Tubulin demonstrates equal loading. (e-h) Embryos were injected with 1 ng 
WT skp2 (e,g) or 1 ng FBox skp2 (f,h) mRNA, along with ßgal mRNA as a lineage tracer, in one blastomere at the two cell stage. Embryos 
were analyzed for expression of muscle actin (e,f) or heavy chain myosin expression (g,h) at stage 15. Dorsal views with injected side to 
the right.Neural Development 2007, 2:27 http://www.neuraldevelopment.com/content/2/1/27
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role in early Xenopus development of skp2, a component
of the E3 ligase SCFskp2 previously shown to be important
for cell cycle regulation.
In situ hybridisation demonstrates that the developmental
expression of skp2 is dynamic and is consistent with skp2
playing a role in neurogenesis (Figure 1). At early neural
plate stages, skp2 is expressed in anterior regions corre-
sponding to the neuronal placodes, eye field and brain,
and the lateral neural folds where neuronal precursors are
abundant, but is excluded from medial regions of the pos-
terior neural plate. Expression in the neural plate at this
time overlaps at least partially with that of its potential tar-
get, Xic1, although while Xic1 expression is confined to
the deep layer of cells in the neural plate, skp2 mRNA is
found in both the deep and superficial layers (Figure 1h).
As neurulation progresses, skp2 becomes upregulated
throughout the neural tube, although remaining most
prominent in the anterior regions, including in the eye
and in the migrating neural crest of the branchial arches.
At later stages skp2 staining is lost in the posterior of the
embryo, although it remains high in the head. Thus, the
timing and localisation of skp2 message are consistent
with it playing a role in regulation of Xic1 stability and
primary neurogenesis. It is of note that Xic1 is also
strongly expressed in the myotome (Figure 1c, i), where it
is required for muscle differentiation, but skp2 is not
expressed in this tissue (Figure 1h), indicating that any
role of skp2 in regulating Xic1 levels may be confined to
neural tissue.
The effect of skp2 over-expression on neural differentiation is partially rescued by extra Xic1 Figure 7
The effect of skp2 over-expression on neural differentiation is partially rescued by extra Xic1. (a-c) Embryos were injected with wild-
type skp2 (a) or wild-type Xic1 (b) mRNA alone, or together (c), in one blastomere at the two cell stage. ßgal mRNA was co-injected as 
a lineage tracer. Embryos were analyzed for expression of nßt mRNA at stage 15. Dorsal views with injected side to the right. (d) Per-
centages of embryos with mild increase, no change, or moderate or substantial reduction of nßt-positive cells on the injected side relative 
to the uninjected side (see Additional file 1 for photographs of representative embryos).Neural Development 2007, 2:27 http://www.neuraldevelopment.com/content/2/1/27
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SCFskp2 has a known role in cell cycle progression, which
it effects by controlling the levels of a number of key cell
cycle regulators, including cdkis, E2F and c-myc [10-
14,29-32]. We investigated the effect of up- or down-reg-
ulation of skp2 levels on cell cycling by measuring pH3
staining, a specific marker for mitotic cells [33]. Surpris-
ingly and in contrast to the mouse, loss of skp2 protein
had no effect on cell proliferation in early Xenopus
embryos (Figure 2f, h). One of the major points of regula-
tion for progression through the cell cycle is called the
restriction point, found in G1. Passage through the restric-
tion point and, thus, commitment to cell cycling is con-
trolled by phosphorylation of the retinoblastoma (pRb)
protein. This results in release of the transcription factor
E2F, which in turn drives transcription of genes required
for S phase progression (for a review, see [60]). pRb phos-
phorylation is brought about by cdks, which are in turn
inhibited by cdkis. Both cdkis and E2F are targets for skp2-
mediated ubiquitination and destruction. Loss of skp2 in
mammalian cells results in cdki accumulation [25], which
will cause pRb to be maintained in a hypophosphorylated
and, therefore, active state, thus inhibiting passage
through G1 into S phase. Interestingly, at the early stages
of Xenopus development studied here, E2F is found largely
unbound to pRb [61] and, moreover, the Xenopus Rb pro-
tein is not required for cell cycle regulation or early embry-
onic development [62]. Additionally, another potential
skp2 target, c-myc, is predominantly expressed in the neu-
ral crest during early development in Xenopus and loss of
protein after morpholino injection has little effect on cell
proliferation [63]. These observations may explain why
loss of skp2 protein does not affect cell cycling at these
stages, and indicates that c-myc and E2F are not likely tar-
gets for skp2 regulation at this stage.
Absolute levels of skp2 protein are regulated through the
cell cycle, being higher in S and G2 phases [34], indicating
that the absolute level of skp2 protein is important for its
cell cycle function. One characteristic of cancer cells is
inappropriate division, and indeed a variety of tumour
cells have elevated skp2 levels [38,56]. Moreover, over-
expression of skp2 drives entry into S phase, inducing qui-
escent fibroblasts to replicate their DNA in low serum
[30]. Surprisingly, over-expression of skp2 in Xenopus
embryos results in a small but significant decrease in pH3-
staining cells (Figure 3d). However, this decrease is also
seen after over-expression of skp2 in which the F box has
been deleted and which is severely impaired in its ability
to bind to the SCF complex (Figure 3e). Thus, this effect
cannot be due to ubiquitin-mediated proteolysis of
SCFskp2 targets. However, it is possible that skp2 binding
disrupts the function of one of its targets, a positive cell
cycle regulator, resulting in slowing of the cell cycle,
although in this developmental context it is not clear what
such a substrate would be. It has been suggested that in
some cases, cdkis at low levels may be required for assem-
bly of cdk complexes, so can act to stimulate the cell cycle,
only becoming inhibitory above a certain stoichiometry
[64]. Binding by skp2 or F Box skp2 could disrupt this
function. However, disruption of such a function of Xic1
in cdk complex assembly could not account for the F Box-
dependent requirement for skp2 in primary neurogenesis.
Skp2 levels regulate primary neurogenesis in Xenopus; loss
of skp2 results in formation of extra neurons (Figure 2)
while skp2 over-expression inhibits neurogenesis (Figure
3). In vitro studies have shown that Xic1 is a potential tar-
get for skp2-mediated ubiquitination and destruction;
skp2 can target Xic1 for degradation both in vitro and in
vivo [21] (Figure 6). Supporting this hypothesis, Xic1 is
required for primary neurogenesis; in its absence primary
neurons do not form, mimicking the effect of skp2 over-
expression, while over expression of Xic1 results in super-
numery neurons within the usual stripes [22], similar to
the pattern seen on injection of skp2 Mo. Interestingly,
although Xic1 is a cdk inhibitor, it is not required for neu-
rogenesis at the time of cell cycle exit, downstream of Neu-
roD. Instead, Xic1 acts at an early stage of neurogenesis in
parallel with XNgnr1, the same point at which skp2 acts.
Therefore, skp2 may regulate primary neurogenesis by tar-
geting Xic1 for ubiquitin-mediated proteolysis. Most
identified substrates of skp2 require cell cycle regulated
phosphorylation, generally by cdks, to facilitate skp2
binding. Unusually, ubiquitination by SCFskp2 does not
require the phosphorylation of Xic1 [21], indicating that
Xic1 levels will be particularly sensitive to absolute levels
of skp2 protein.
XNgnr1 over-expression induces extra neurons in neur-
oectoderm but this is blocked by skp2 over-expression.
Can extra Xic1 rescue this loss of ectopic neurons? At the
levels injected here, the co-injection of Xic1, skp2 and
XNgnr1 frequently results in apoptosis, precluding further
investigation. This may be a result of the combined mild
pro-apoptotic effects of both XNgnr1 and Xic1 [22,65]
when they are co-injected. We would note, however, that
Xngnr1 is the endogenous driver of formation of primary
neurons in the normal stripes, these are suppressed by
over-expression of skp2, and a partial rescue occurs when
skp2 and Xic1 are co-injected. We show that Xic1 is
required for normal primary neurogenesis, it is degraded
by skp2, and a drop in its levels is crucial for over-
expressed skp2 to inhibit neurogenesis in the neural plate.
Thus, skp2 is perfectly placed to regulate Xic1 levels result-
ing in control of differentiation of primary neurons in
vivo.
Over-expression of skp2 results in degradation of a signif-
icant proportion of co-expressed Xic1 protein (Figure 6b,
c). However, increasing the amount of skp2 further doesNeural Development 2007, 2:27 http://www.neuraldevelopment.com/content/2/1/27
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not result in full degradation of Xic1. In these assays, Xic1
is continually synthesised from micro-injected message
and the level of remaining protein may represent an equi-
librium between synthesised and degraded Xic1 protein.
In addition, at high levels of skp2, it is likely that other
components of the Scf E3 ligase complex become limit-
ing. Skp2 mRNA injection has a small but somewhat
inconsistent effect on levels of endogenous Xic1 protein
in whole embryos that is made up of expression in epider-
mal, neural and mesodermal tissues. However, by dissect-
ing out the neural plate and neural folds at mid-neurula
stage, we can enrich for the population of endogenous
Xic1 protein in differentiating primary neurons compared
to mesodermal and epidermal Xic1, and when we do this
we see that skp2 can target endogenous Xic1 for destruc-
tion more efficiently (Figure 6d). Xic1 plays an essential
role in muscle differentiation [26]. Interestingly, while
skp2 over-expression inhibits neurogenesis, we see that it
does not inhibit myotomal muscle differentiation (Figure
6e–h), indicating that it is unable to degrade Xic1 protein
in the myotome. This could be due to either lack of other
SCF complex members, modification or degradation of
skp2 protein, modification of Xic1 or another unknown
mechanism. Indeed, endogenously, skp2 is not expressed
in muscle so the absence of any required co-factors might
not be unexpected.
The mammalian homologue of Xic1, p27Kip1, is also tar-
geted for ubiquitin-mediated proteolysis by the ubiquitin
ligase KPC, where its destruction occurs after export from
the nucleus [66]. Homologues of its components KPC1
and 2 are found in Xenopus and are well conserved (76%
and 73% identity with human KPC1 and 2, respectively;
C Fiore-Heriche and AP, data not shown). Xic1 destruc-
tion in Xenopus eggs requires Xic1 to be in the nucleus
[67], although it is not known whether later in develop-
ment there may be an additional cytoplasmic Xic1
destruction pathway. As skp2 is not expressed in the myo-
tome, such a pathway may control Xic1 levels in the devel-
oping muscle.
To determine further whether skp2 is acting on neurogen-
esis via its ability to regulate Xic1 levels, we investigated
the effect of co-expression of skp2 and Xic1 on formation
of primary neurons (Figure 7). Overexpression of skp2
inhibits neurogenesis while increasing Xic1 levels pro-
duces extra neurons: co-injection of the two results in an
intermediate phenotype, demonstrating that a balance
between levels of skp2 and Xic1 proteins regulates the
number of differentiating primary neurons, again indicat-
ing that Xic1 is a bone fide in vivo substrate of SCFskp2.
However, it should be noted that Xic1 protein expressed
from injected mRNA accumulates to levels far higher than
those usually found in embryos (Figure 6), yet rescue is
not complete. We favour the possibility that there are
unknown protein targets of SCFskp2, in addition to Xic1,
that are involved in primary neuron differentiation, and
that their stability is regulated in parallel with Xic1; levels
of Xic1 and this additional target(s) must be restored to
fully rescue primary neurogenesis in the presence of ele-
vated skp2 protein. XNgnr1, the proneural protein that
drives primary neurogenesis, is unstable but our prelimi-
nary data indicate it is unlikely to be a direct target of
ubiquitin-mediated proteolysis by SCFskp2 (J Vosper, HB-P
and AP, unpublished data). However, other cell cycle reg-
ulators known to be targets of SCFskp2, such as E2F1 [10]
and c-myc [11,12], could play additional roles in regulat-
ing neuronal differentiation.
In conclusion, here we demonstrate a role for skp2 in reg-
ulating differentiation of primary neurons over and above
any role it may have in regulating the cell cycle. Indeed, in
Xenopus, at these early developmental stages, skp2's role in
cell cycle progression appears to be minimal. Skp2 is
widely expressed in the developing mouse so it is well
placed to play a role in differentiation in mammalian
embryos in addition to a role in cell cycle regulation.
Cancer cells divide inappropriately, but equally important
is their failure to adopt a fully differentiated character and
it is this that results in malignancy. Indeed, cancer may
result from a failure to differentiate rather than from cell
cycle defects per se [68] with cells reverting to a more
embryonic phenotype. Skp2 is elevated in a range of
tumours [38,56], where our data indicate it may play a
separable but complementary role in regulating cell cycle
progression and differentiation. We would argue that any
direct role in differentiation must be explained to under-
stand the full impact of skp2 upregulation in cancer. In
general, molecules that regulate cell cycle exit and differ-
entiation may be crucial targets for cancer therapy, and if
we are to make the best use of them we must have a greater
understanding of how cell division and differentiation are
co-ordinated during development. Identifying molecules
with dual functions in these two processes is a good place
to start.
Materials and methods
Plasmid construction and mutagenesis
To create skp2 without the F-box domain (F Box skp2),
two separate fragments flanking the region to be deleted
were amplified from skp2 plasmid DNA, using Taq and
Vent DNA polymerases. The first fragment (amino acids
1–92 of wild-type skp2) was amplified using primers 5'-
CGC AGG GAA TTC GCC ACC ATG CAC AGG AAA CAT
CTT CAG GAG ATC TCG-3' and 5'-CGC AGT ACC GGT
GAC TGA CTG AGC AAG-3'. The second fragment (amino
acids 138–420) was amplified using primers 5'-GTC AGG
ACC GGT GAT CTT ACT GGC AAA CAC GTG-3' and 5'-
GCA CGC TAG GCC TTC ACA AGT AGT CCT TAT AGTNeural Development 2007, 2:27 http://www.neuraldevelopment.com/content/2/1/27
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TCA-3'. The PCR products were digested with EcoRI/AgeI
(fragment 1) or AgeI/StuI (fragment 2) and subcloned into
the EcoRI/StuI sites of pCS2+.
RNA/morpholino oligonucleotide injections
For generating capped mRNAs, vectors encoding XNgnr1
[23], XNeuroD [24], skp2, F-Box skp2, MAFbx, and ßgal
were transcribed in vitro (mMessage mMachine Kit,
Ambion (Applied Biosystems, Warrington UK). RNAs for
XNgnr1 (50 pg), NeuroD (500 pg), skp2 (1 ng), F-Box
skp2 (1 ng) or MAFbx (1 ng) were co-injected in a volume
of 10 nl along with 100 pg of ßgal mRNA to act as a line-
age tracer. Antisense morpholino oligonucleotide skp2
Mo (20–40 ng; 5'-ATG TTT ACC TGT GCA TGT TCA TCA
G-3') or a five base-pair mismatch control morpholino
(30–40 ng; 5'-ATC TTT AGC TCT GCA TCT TCT TCA G-3')
(GeneTools LLC Philomath, Oregon, USA.), were also
coinjected with 100 pg of ßgal mRNA.
Xenopus whole-mount in situ hybridisation, antibody 
staining, and in situ hybridisation on sections
Embryos were raised until indicated stages, fixed in
MEMFA for 1.5 hours, X-gal (5-bromo-4-chloro-3-indolyl
β-galactopyranoside) stained and analyzed by whole
mount in situ hybridisation [69]. Double in situ hybridisa-
tions were performed according to [70]. Linearised plas-
mids from Sox3 (Not1/T7), Bluescript N-tubulin
(BamH1/T3) [71], pCS2+ (T7 promoter repaired; EcoRI/
T7) skp2 were used to generate antisense RNA probes by
in vitro transcription with digoxigenin-11-UTP (Roche,
Welwyn Garden City, UK.) and detected using alkaline-
phosphatase-conjugated anti-digoxigenin antibodies
(Roche). BM purple was used as a substrate (Roche). pH3
immunostaining was carried out as previously described
[72] using a 1:1,000 dilution of primary antibody anti-
pH3 (TCS Biologicals, Buckingham, UK.) pH3-positive
cells were counted within regions of equal surface area on
injected and uninjected bilateral halves of each embryo;
percent changes were then determined for each embryo as
the ratio of injected/uninjected values. Percent values
shown represent averaged results. In situ hybridisation on
tissue sections was carried out as previously described
[73]. Alternatively, embryos were post-fixed in MEMFA,
embedded in gelatin/albumin and sectioned by Leica
VT1000M vibratome, and mounted in 100% glycerol, (60
micron sections; Figure 1h, i). In Figure 1i, staining of
deep mesodermal tissues appears light blue due to poor
penetrance of the BM purple staining component.
Western blotting
Protein extracts were prepared as previously described
[61]. Skp2 was detected using an affinity purified polyclo-
nal antibody [21], p27Xic1 was detected using an affinity
purified polyclonal antibody [21]. Blots were probed with
monoclonal anti-tubulin antibody (1: 2,000; Sigma, Gill-
ingham, UK) where appropriate as a loading control. Usu-
ally, protein from approximately one embryo equivalent
or five dissected neural plates was loaded per lane.
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